GLUCOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Glucose Health, Inc.
Financials through Q3 FY2017, quarter ended Sep 30, 2017Last filing: 10-Q on Nov 14, 2017
$0.44+0.10 (+28.76%)
Close on Oct 19, 2026
- Market cap
- $1.82M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2009 to 2016
Gross margin
6.1%
Operating margin
-27.7%
Net margin
-131.0%
Growth rates
Compound annual growth to fiscal 2016
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +7232.1% | +1018.2% | – | – | |
| Gross profit | +4728.0% | – | – | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2009 | FY2011 | FY2016 | Trend |
|---|---|---|---|---|
| Return on equity | – | 230.4% | 92.9% | |
| Return on assets | – | -559.4% | -1690.7% | |
| Current ratio | – | 0.06 | 0.06 | |
| Interest coverage | – | -85.7× | -0.3× | |
| Inventory turnover | – | – | – | |
| Diluted shares | – | 0M | 3M |
Cash use needs five years of cash flow figures
Glucose Health does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-131.0%
×Asset turnover12.90×
×Equity multiplier-0.05×
=Return on equity, FY201692.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2016 | -131.0% | 12.90× | -0.05× | 92.9% |
| FY2015 | -6228.1% | 0.14× | -0.09× | 79.6% |
| FY2014 | -24439.9% | 0.08× | -0.15× | 279.9% |
| FY2013 | -651404.5% | 0.00× | -1.33× | 1662.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2016 against fiscal 2015
3of 8 tests passed in fiscal 2016. Some tests lack the figures they need.
- ProfitableNet income above zero-$410.44K
- Cash generatingOperating cash flow above zero-$39.26K
- Return on assets improvedROA up on the prior year-604.3% → -2664.0%
- Earnings backed by cashOperating cash flow above net income-$39.26K vs -$410.44K
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.04 → 0.06
- No dilutionShare count did not rise2M → 3M
- Gross margin improvedGross margin up on the prior year9.29% → 6.12%
- More efficientAsset turnover rose0.10 → 20.33